Physician profile
Maria Maruffi
NPI 1609175918
$1,868.29
in general payments reported to CMS, 2019-2025
11 companies · $304 in 2025
The $304 reported for 2025 was more than what a typical Pediatric Hematology-Oncology provider received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $513 · 2023: $522 · 2024: $529 · 2025: $304.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,355.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $477.59 | 2022-2025 | |
| Novo Nordisk INC | $248.13 | 2022 | |
| Servier Pharmaceuticals LLC | $236.54 | 2023 | |
| Adaptive Biotechnologies Corporation | $185.66 | 2022-2024 | Clonoseq |
| Alexion Pharmaceuticals, INC. | $121.36 | 2024 | Koselugo |
| Uswm, LLC | $119.09 | 2024 | Iwilfin |
| Btg International INC. | $117.88 | 2024 | |
| Springworks Therapeutics, INC. | $116.37 | 2025 | Ogsiveo |
| Janssen Scientific Affairs, LLC | $109.52 | 2023 | Xarelto |
| Syndax Pharmaceuticals, INC. | $101.76 | 2025 | Revuforj |
| Day One Biopharmaceuticals | $34.39 | 2024-2025 | Ojemda |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Maruffi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.